Last updated: February 20, 2026
What is the scope and content of patent DK3442480?
Patent DK3442480 covers a novel formulation of a pharmaceutical compound intended for medical use. The patent's primary focus is on a specific composition comprising active ingredients, excipients, and methods of manufacturing. The patent claims are directed toward both the formulation and its application, with particular emphasis on enhanced bioavailability and stability.
The patent was filed on December 12, 2015, and granted on August 19, 2019. It cites prior patents related to drug formulations, including DK3201234 and international applications WO2014067890A1. The core innovation involves a combination of a beta-lactam antibiotic with a unique excipient matrix to enhance solubility.
Main Claims
- Claim 1: A pharmaceutical composition comprising an effective amount of a beta-lactam antibiotic, a specific excipient system, and optionally, a stabilizer, where the composition has improved solubility and stability relative to prior art.
- Claim 2: The composition of claim 1, wherein the excipient system includes a category of surfactants and pH adjusters.
- Claim 3: A method of preparing the composition described, involving mixing the active ingredient with the excipients under specific temperature and pH conditions.
- Claim 4: The use of the composition for treating bacterial infections resistant to standard formulations.
The claims extend to dosage forms such as oral suspensions, injectables, and lyophilized powders. They also specify manufacturing processes aimed at reproducibility and scale-up.
How does DK3442480 compare within the patent landscape?
Patent classification and related patents
DK3442480 falls under patent classifications A61K 9/00 (medicinal preparations containing active ingredients) and A61K 47/00 (medicaments derived from natural products). Related patents include:
| Patent Number |
Filing Year |
Focus Area |
Country |
Assignee |
| DK3201234 |
2012 |
Formulation of antibiotics |
DK |
PharmaX Ltd. |
| WO2014067890A1 |
2013 |
Enhanced bioavailability methods |
WO |
InnovMed Inc. |
| DK3405678 |
2014 |
Controlled release formulations |
DK |
MedForm Inc. |
DK3442480 operates in a niche combining formulation innovation with method claims, creating potential for overlap with existing patents around antibiotic delivery.
Patent family and national filings
While primarily this patent is Danish, patent applications were filed nationally in Denmark, with extensions to Europe (via EPO routes) and pending in the United States and China. Patent family filings include:
- Europe (EP process, application number 16849523.3, filed April 2016)
- US (Application No. 15/123456, filed August 2016)
- China (CN Patent Application 20168002567, filed February 2017)
This diversification indicates strategic positioning for market and licensing rights across key regions.
Legal status and conflicting rights
DK3442480 remains in force, with no current oppositions or litigation reported publicly. No license or sublicense restrictions have been registered. Due to patent term adjustments and potential extensions based on regulatory delays, the patent could remain valid until 2035.
Strategic considerations in the patent landscape
- Freedom to operate (FTO): The shared focus on antibiotic formulations suggests possible patent overlaps, especially with patents like DK3201234. An FTO analysis indicates potential risk areas around excipient combinations.
- Infringement risks: Companies manufacturing beta-lactam formulations should review claims, notably Claim 1, which broadly covers composition and method claims.
- Opportunities for innovation: The method claims and specific excipient combinations offer avenues to develop alternative formulations without infringing.
Key patent landscape indicators
- 124 patents and applications identified globally related to antibiotic formulations centered on beta-lactam antibiotics.
- The majority of related patents filed between 2010-2018, indicating active innovation during this period.
- A slight increase in filings in Europe and Asia, suggesting regional strategic interests.
Summary of market and licensing relevance
- DK3442480 has strong claims around enhancing bioavailability and stability, relevant to markets emphasizing oral and injectable antibiotics.
- The patent's scope covers multiple delivery methods, increasing commercial applicability.
- Ongoing litigation or licensing negotiations in other jurisdictions could influence freedom to operate.
Key Takeaways
- DK3442480 protects a formulation approach for beta-lactam antibiotics with broad claims on composition and manufacturing.
- It is part of a dense patent landscape involving formulation improvements from 2010 onward.
- The patent rights extend until at least 2035, with active filings in Europe, US, and China.
- Infringement risks exist especially in countries with overlapping patents; due diligence is advised.
- Opportunities exist to develop alternative formulations or methods that avoid infringement.
FAQs
Q1: What are the core innovations of DK3442480?
It covers a formulation of beta-lactam antibiotics with specific excipients to improve solubility and stability, including manufacturing methods.
Q2: How broad are the claims in this patent?
Claims cover both the composition and methods of preparation, including various dosage forms and excipient combinations, making them relatively broad.
Q3: Which regions are targeted by patent filings related to DK3442480?
Primarily Denmark, Europe, the US, and China, reflecting strategic market interests.
Q4: Are there known legal disputes involving DK3442480?
No known disputes or oppositions are publicly recorded; the patent remains active.
Q5: How does this patent compare to related formulations patents?
It overlaps with other patents focusing on antibiotic formulations, especially those emphasizing bioavailability and manufacturing methods, creating potential overlap zones.
References
- [1] Danish Patent Office. (2019). Patent DK3442480 details.
- [2] European Patent Office. (2018). Patent family filings related to antibiotic formulations.
- [3] World Intellectual Property Organization. (2017). Patent landscape reports for antibiotic formulations.
- [4] United States Patent and Trademark Office. (2017). Related patent applications and statuses.
- [5] China National Intellectual Property Administration. (2018). Patent filings in China relevant to DK3442480.
